After the Association for Accessible Medicines’ (AAM’s) Access! 2019 annual meeting came to a close last week, The Center for Biosimilars® spoke with Christine Simmon, senior vice president of policy and strategic alliances, AAM, and executive director, AAM’s Biosimilars Council, to get her take on some of the outcomes of the meeting.
After the Association for Accessible Medicines’ (AAM’s) Access! 2019 annual meeting came to a close last week, The Center for Biosimilars® spoke with Christine Simmon, senior vice president of policy and strategic alliances, AAM, and executive director, AAM’s Biosimilars Council, to get her take on some of the outcomes of the meeting.
“I think one of the biggest takeaways from the meeting was the continuing importance of biosimilars. Of course, we had a dedicated biosimilars session, but biosimilars really came up in every session, and I thought that was very telling,” said Simmon.
The biosimilars session she referenced included a panel during which various biosimilar stakeholders and industry experts discussed how to identify and address “biosimilar shenanigans.” The opening presenter of the session, Carol Lynch, president of Sandoz US and head of North America, explained that data show that if all FDA-approved biosimilars had been marketed in a timely manner, Americans could have saved $4.5 billion.
Simmon touched upon this issue as well, stating that “There are significant concerns about the viability and ultimately the sustainability in the [United States].” Interestingly, Simmon noted that in her own discussions with meeting attendees, she “heard recognition from more people that the European successes around biosimilars—which are still very praise worthy—is evolving there to a sustainability issue as well.” She stressed that while the US biosimilar market has not nearly reached its peak, stakeholders need to start planning ahead for the sustainability of the market.
The importance of the biosimilars market, as well as the savings it could achieve for patients, was referenced also in the closing keynote address delivered by HHS Secretary Alex Azar. “Biologic drugs, today, represent almost 40% of prescription drug spending. The challenges are real, but so is the potential for competition and savings. Imagine doing to 40% of the pharmaceutical market just some fraction of what generics have already done to the other 60%,” said Azar. He went on to discuss how he intends to achieve these savings and increased uptake in biosimilars: pharmacy-level interchangeability.
Simmon explained that interchangeability has been a hot topic for AAM’s Biosimilars Council, too. “A major focus area for the council is educating around interchangeability and misinformation. Not even so much how to do interchangeability, but to some degree, I guess you could say the interplay between interchangeability designations and market uptake,” she said. “It’s another misconception—and we’ve heard this misconception among payers and physicians as well—that they’re waiting for interchangeability to really get on board with biosimilars.”
FDA has been working on finalizing a guidance around interchangeability and how biosimilar developers can achieve the designation. The guidance is expected to be released in the upcoming months.
Eye on Pharma: Bevacizumab Update; Samsung Bioepis, J&J Settlement; Another EU Trastuzumab
December 6th 2023Outlook Therapeutics provides an update on the development of its bevacizumab candidate for age-related macular degeneration; Samsung Bioepis settles with Johnson & Johnson (J&J) over its ustekinumab biosimilar candidate; and the European Union gains another trastuzumab biosimilar.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Study Documents HCPs’ Experiences of a Mandatory Switch to Inform Future Transitions
December 2nd 2023A survey explores the experiences of health care providers (HCP) in New Zealand throughout the transition process following a mandatory switch from the adalimumab originator (Humira) to a biosimilar in 2022.
Biosimilars Business Roundup For August 2023—Podcast Edition
September 5th 2023On this episode, we’re giving an overview of some of the biggest stories in the business space regarding biosimilars, like the approval of the first neurology biosimilar, growth projections from company quarterly expense reports, and some analyses about the health of the market.
CVS Caremark Switches Up Biosimilar Coverage in 2024
November 27th 2023As new biosimilars are added to CVS Caremark’s standard formulary, others are removed. One notable change is with the Humira biosimilars: the pharmacy benefit manager has removed Amjevita in favor of Hyrimoz and an unbranded biosimilar.